BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khair RM, Nwaneri C, Damico RL, Kolb T, Hassoun PM, Mathai SC. The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. Ann Am Thorac Soc 2016;13:842-9. [PMID: 26974862 DOI: 10.1513/AnnalsATS.201512-824OC] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Blánquez Moreno C, Colungo Francia C, Alvira Balada MC, Kostov B, González-de Paz L, Sisó-Almirall A. [Effectiveness of an educational program for respiratory rehabilitation of Chronic Obstructive Pulmonary Disease patients in Primary Care in improving the quality of life, symptoms, and clinical risk]. Aten Primaria 2018;50:539-46. [PMID: 28987858 DOI: 10.1016/j.aprim.2017.03.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Banerjee D, Kamuren J, Baird GL, Palmisciano A, Krishnan I, Whittenhall M, Klinger JR, Ventetuolo CE. The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. Pulm Circ 2017;7:384-90. [PMID: 28597751 DOI: 10.1177/2045893217695568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Zeng Y, Jiang F, Chen Y, Chen P, Cai S. Exercise assessments and trainings of pulmonary rehabilitation in COPD: a literature review. Int J Chron Obstruct Pulmon Dis 2018;13:2013-23. [PMID: 29983556 DOI: 10.2147/COPD.S167098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
4 Zha LH, Zhou J, Li TZ, Luo H, He JN, Zhao L, Yu ZX. NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis. Aging Dis 2018;9:843-51. [PMID: 30271661 DOI: 10.14336/AD.2017.1102] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Barnes H, Yeoh HL, Fothergill T, Burns A, Humbert M, Williams T. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev 2019;5:CD012785. [PMID: 31042010 DOI: 10.1002/14651858.CD012785.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
6 Naci B, Demir R, Onder OO, Sinan UY, Kucukoglu MS. Effects of Adding Respiratory Training to Osteopathic Manipulative Treatment on Exhaled Nitric Oxide Level and Cardiopulmonary Function in Patients With Pulmonary Arterial Hypertension. Am J Cardiol 2022;162:184-90. [PMID: 34706819 DOI: 10.1016/j.amjcard.2021.09.023] [Reference Citation Analysis]
7 Huang B, Niu Y, Zhao W, Bao P, Li D. Reduced Sleep in the Week Prior to Diagnosis of COVID-19 is Associated with the Severity of COVID-19. Nat Sci Sleep 2020;12:999-1007. [PMID: 33209069 DOI: 10.2147/NSS.S263488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
8 George MP, Gladwin MT, Graham BB. Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine. Am J Respir Cell Mol Biol 2020;63:279-92. [PMID: 32453969 DOI: 10.1165/rcmb.2020-0099TR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Paolucci T, Pezzi L, Bellomo RG, Spacone A, Giannandrea N, Di Matteo A, Prosperi P, Bernetti A, Mangone M, Agostini F, Saggini R. Tailored patient self-management and supervised, home-based, pulmonary rehabilitation for mild and moderate chronic obstructive pulmonary disease. J Phys Ther Sci 2022;34:49-59. [PMID: 35035080 DOI: 10.1589/jpts.34.49] [Reference Citation Analysis]
10 Li H, Yang Z, Gao F, Zhang Y, Meng W, Rong S. MicroRNA-17 as a potential diagnostic biomarker in pulmonary arterial hypertension. J Int Med Res 2020;48:300060520920430. [PMID: 32600075 DOI: 10.1177/0300060520920430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Costi S, Tonelli R, Brogneri A, Florini F, Tilocca N, Vicentini M, Baroncini S, Cerulli M, Clini E. Changes in Clinical Characteristics and Outcomes of Patients Admitted to Inpatient Cardiac Rehabilitation. Int J Environ Res Public Health 2021;18:8871. [PMID: 34444621 DOI: 10.3390/ijerph18168871] [Reference Citation Analysis]
12 Swiatek KM, Lester C, Ng N, Golia S, Pinson J, Grinnan D. Impact of Face Masks on 6-Minute Walk Test in Healthy Volunteers. Pulm Circ 2021;11:2045894020988437. [PMID: 33532062 DOI: 10.1177/2045894020988437] [Reference Citation Analysis]
13 Anlló H, Herer B, Delignières A, Bocahu Y, Segundo I, Mach Alingrin V, Gilbert M, Larue F. Hypnosis for the Management of Anxiety and Dyspnea in COPD: A Randomized, Sham-Controlled Crossover Trial. Int J Chron Obstruct Pulmon Dis 2020;15:2609-20. [PMID: 33122899 DOI: 10.2147/COPD.S267019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev 2019;1:CD012621. [PMID: 30701543 DOI: 10.1002/14651858.CD012621.pub2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
15 Ni Z, Wang K, Wang T, Ni Y, Huang W, Zhu P, Fan T, Wang Y, Wang B, Deng J, Qian Z, Liu J, Cai W, Xu S, Du Y, Wang G, Liang Z, Li W, Luo J, Luo F, Liu D. Efficacy of early prone or lateral positioning in patients with severe COVID-19: a single-center prospective cohort. Precision Clinical Medicine 2020;3:260-71. [DOI: 10.1093/pcmedi/pbaa034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2021;3:CD004434. [PMID: 33765691 DOI: 10.1002/14651858.CD004434.pub6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J 2019;53:1801908. [PMID: 30545975 DOI: 10.1183/13993003.01908-2018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 25.0] [Reference Citation Analysis]